June 18 (Reuters) – ROCHE HOLDING AG: * FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ROCHE’S LUNSUMIO AND POLIVY COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)